Akari Therapeutics Plc
AKTX Nasdaq
SEC CIK 1541157
Follow Akari Therapeutics
Weekly email: filings, results
Net income
−$4.8M
+24.3% vs same quarter last year
EPS, diluted
$0.00
Operating cash flow
−$4.2M
−99.2% vs same quarter last year
Operating income
−$4.7M
+36.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$17.3M |
| FY24 | −$19.8M |
| FY23 | −$10M |
| FY22 | −$13.1M |
| FY21 | −$17.4M |
| FY20 | −$17.1M |
| FY19 | −$16.8M |
| FY18 | −$20.5M |
| FY17 | −$35.4M |
| FY16 | −$18.1M |
| FY15 | −$45.3M |
| FY14 | −$1.9M |
| FY13 | −$3.6M |
| FY12 | −$4.3M |
| FY11 | −$2.1M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$16.4M |
| FY22 | −$7.6M |
| FY21 | - |
| FY20 | - |
| FY19 | −$12.9M |
| FY18 | −$22.8M |
| FY17 | −$31.6M |
| FY16 | −$24.7M |
| FY15 | −$5M |
| FY14 | −$1.5M |
| FY13 | −$5.5M |
| FY12 | −$2.1M |
| FY11 | −$1M |